Regeneron Pharmaceuticals’ (REGN) “Outperform” Rating Reaffirmed at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Monday,Benzinga reports. Oppenheimer currently has a $865.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $750.00.

Several other research analysts have also recently issued reports on the stock. Scotiabank raised their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Evercore ISI upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $799.74.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $755.02 on Monday. The firm has a fifty day simple moving average of $758.27 and a two-hundred day simple moving average of $652.73. The company has a quick ratio of 4.22, a current ratio of 4.77 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a market capitalization of $79.35 billion, a PE ratio of 18.17, a P/E/G ratio of 1.92 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $12.07 earnings per share. Research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Dodge & Cox increased its position in Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $628,151,000. AQR Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 528.7% in the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after purchasing an additional 606,612 shares during the last quarter. Invesco Ltd. boosted its stake in Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after purchasing an additional 408,649 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan sharply raised its price target to $950 and moved to “overweight,” signaling a sizable upside thesis tied to Regeneron’s recent results and trajectory. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed “outperform” and lifted its target to $865, showing dealer conviction that Q4 results justify higher analyst estimates. Benzinga
• Positive Sentiment: Cantor Fitzgerald and Wells Fargo raised targets (to $800), with Cantor keeping an “overweight” view — reinforcing industrywide upgrades following the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted EYLEA HD Phase 3 presentations at Angiogenesis 2026 (final 64‑week QUASAR and full ELARA results), which support the drug’s clinical profile and could underpin retinal franchise growth. EYLEA HD Presentations
• Positive Sentiment: Investors are digesting the company’s upbeat Q4 report (EPS and revenue beats) and accompanying earnings call commentary that boosted near‑term visibility. Q4 Earnings Transcript
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a modest adjustment that suggests limited conviction for sizable near‑term upside. TickerReport
• Neutral Sentiment: Truist trimmed its target slightly (to $818) but maintained a “buy,” reflecting minor calibration rather than a change in long‑term view. TickerReport
• Neutral Sentiment: Market commentary and pieces on Regeneron’s pipeline vs. valuation highlight a valuation gap and focus investors on execution of key pipeline catalysts over the next 12–24 months. Yahoo Finance

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.